PT-141 in Germany: what the law says

In Germany, PT-141 (bremelanotide) has no marketing authorisation. The EMA central medicines register holds no EPAR, no positive opinion, and no referral for bremelanotide or its brand name Vyleesi^[1], and Germany's national drug regulator, the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), has issued no national authorisation either. That position has not changed in the past 12 months. What has changed is the research context: two papers published in 2026 updated the evidence base on bremelanotide for sexual dysfunction, and one 2025 Palatin Technologies trial showed an unexpected obesity signal. None of that moves the German regulatory clock.

What German law says about unlicensed medicines

The legal baseline is paragraph 21 of the Arzneimittelgesetz (AMG), Germany's medicines act. It states that finished medicinal products may only be placed on the German market if authorised by the competent federal authority or covered by an EU marketing authorisation under Regulation (EC) No. 726/2004^[2]. Bremelanotide meets neither requirement. It is not centrally authorised by the EMA, and BfArM has granted no national authorisation.

Paragraph 73 of the AMG does create a narrow named-patient exception^[3]. A pharmacy may import a small quantity of an unlicensed medicine for an individual patient if: the medicine is lawfully marketed in the country of export, there is no comparable authorised alternative in Germany, and a physician's prescription accompanies the order. For bremelanotide this means a German physician would need to request it on a named-patient basis from a US pharmacy dispensing authorised Vyleesi, document the individual clinical need, and take personal clinical responsibility for the import. This is a legitimate but narrow route. It is not the same as general availability.

Grey-market research vials labelled 'PT-141' or 'bremelanotide' sold by online vendors sit entirely outside this framework. Those products are not authorised in any country as finished medicinal products and are not lawfully importable under the AMG §73 named-patient route, which requires that the source product be lawfully marketed in the country of export. Research-chemical vials from online vendors do not meet that standard. Customs seizure at the German border is a documented risk for parcels containing unlicensed injectable products.

Why there is no EU authorisation

The FDA approved Vyleesi on 21 June 2019 under NDA 210557, for hypoactive sexual desire disorder (HSDD) in premenopausal women^[4]. The pivotal RECONNECT programme, published by Kingsberg and colleagues in Obstetrics & Gynecology the same year, enrolled approximately 1,267 premenopausal women across two identical randomised trials (BMT-301 and BMT-302) and showed statistically significant improvements on both the FSFI desire domain score and the FSDS-DAO item-13 distress measure versus placebo^[5]. A 52-week open-label safety extension by Simon and colleagues confirmed no new safety signals over longer use^[6].

No sponsor ever filed for EMA centralised authorisation. AMAG Pharmaceuticals held the original US licence and sold the asset to Cosette Pharmaceuticals in 2021 after disappointing US commercial sales. US prescriptions under the Cosette-run BlinkRx programme are priced at $0 for most commercially-insured patients and $99 for uninsured patients per four-dose pack, which reflects the narrow commercial appeal of a drug with roughly 40% nausea rates in a market without insurance mandate coverage. Neither AMAG nor Cosette pursued an EU filing. Originator Palatin Technologies has not publicly disclosed EMA submission plans as of this writing. The EMA procedures that would result in a centrally authorised product for all EU member states, including Germany, have simply never been started.

HSDD is recognised as a diagnosis in Germany and across Europe. The International Classification of Diseases (ICD-10) and European clinical guidelines acknowledge hypoactive sexual desire as a treatable condition. The absence of an EU product is not a regulatory rejection of the indication. It is an absence of a commercial application. That distinction matters in practice: German physicians treating patients with HSDD can consider the named-patient import route specifically because there is no comparable authorised domestic alternative, which is one of the conditions §73 requires.

What changed in the last 12 months

Two research developments are worth noting for readers following the bremelanotide literature, though neither changes the German regulatory position. In 2026, Toledo and colleagues published a systematic review and meta-analysis in the Journal of Minimally Invasive Gynecology (PMID 40543759) that found bremelanotide improved total FSFI scores and both desire and arousal subscales across the included studies^[7]. Pfaus and Balon published a discussion paper in the Journal of Clinical Psychopharmacology (PMID 41960633) asking whether bremelanotide should be considered for sexual arousal and desire disorders in men. These papers extend the published evidence base; they do not constitute regulatory submissions.

Separately, in March 2025 Palatin Technologies announced that BMT-801, a phase-2 study of bremelanotide co-administered with tirzepatide, met its primary weight-loss endpoint. The co-administered group showed a 4.4% reduction in body weight versus 1.6% for placebo. That finding is preliminary, confined to a phase-2 trial, and has not been the subject of any regulatory filing in the EU or in Germany. It does not change the regulatory position of bremelanotide as a standalone product.

What this means for patients in Germany

A patient in Germany with a diagnosed HSDD wanting to consider bremelanotide treatment has one lawful pathway: work with a German physician experienced in sexual medicine who is willing to arrange a named-patient import under AMG §73. That physician takes on responsibility for the import documentation and for the clinical supervision of an unlicensed product. The relevant professional societies are the German Society for Sexual Medicine, Sexual Therapy and Sexual Science (DGSMTW) and the German Society for Urology (DGU). Neither society has issued a formal position statement on bremelanotide as of this writing. In practice, physicians in sexual medicine and gynaecology clinics in larger German cities, particularly university medical centres in Berlin, Hamburg, Munich and Cologne, are the most likely to have familiarity with this route. Any general practitioner wishing to arrange named-patient supply would typically refer the patient to a specialist first, both for the diagnosis confirmation that HSDD requires and for the prescriber experience the unlicensed import process calls for.

The safety profile that any prescribing German physician would be working from is the US Vyleesi label^[4]. The label's key warnings are relevant regardless of jurisdiction: uncontrolled hypertension and known cardiovascular disease are contraindications; nausea occurs in roughly 40% of treated women, peaking after the first dose; and focal hyperpigmentation of the face, gums or breasts affects roughly 1% of patients at the recommended dosing frequency, with the label noting the pigmentation may not fully resolve after discontinuation. Those contraindications and safety signals apply to any use, including named-patient supply.

For readers outside the named-patient route: ordering grey-market PT-141 vials online and shipping them to a German address is not the same as importing an authorised medicine. Those products are uncharacterised for identity, purity and potency under EU pharmaceutical standards, carry no BfArM oversight, and do not have the prescriber accountability the named-patient framework requires. The blood-pressure signal that halted the original Palatin intranasal programme in 2007 remains a relevant safety reference for any product in this class: bremelanotide does produce transient cardiovascular effects, and dosing an uncharacterised vial without a clinical cardiovascular screen carries risks the RECONNECT trial programme managed under controlled conditions.

What is not covered here

This article covers bremelanotide's regulatory position in Germany only. For the cross-country picture across all jurisdictions PeptideMethods tracks, see the PT-141 regulation overview. For the mechanism of action, the full RECONNECT evidence base, and the safety profile in detail, see the PT-141 main page. This article does not address the German regulatory position for flibanserin (Addyi), the other FDA-approved HSDD drug, which has its own separate non-EU authorisation history.

The regulatory status shown here reflects the position as of June 2026. Regulations can change: a sponsor could file for EMA authorisation, the EMA could grant it, and BfArM's position would update automatically for the German market if a centrally-authorised product emerged. Verify the current position directly with BfArM or with a German regulatory specialist before making any clinical or legal decision. For the WHO classification context, bremelanotide is assigned ATC code G02CX05 under the 'other gynecologicals' category^[8], which reflects the narrow approved indication and the absence of broader approved uses.